Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2020

View Archived Issues

Amgen studies AMG-256 for advanced solid tumors in phase I trial

Following neonatal lead enables spinal cord repair in mice

T-cell 'repliclones' can thwart HIV drugs

Fat-free mice have bigger bones

Test tube HIV enables replication insights

Jiangsu Provincial Center for Disease Control and Prevention patents anti-coronavirus MAbs

Kinnate Biopharma discovers c-RAF inhibitors

Topline phase III results show noninferiority of OPC-61815 versus tolvaptan tablets

Exciting toxicity study implicates TRPM4 in NMDA-mediated cell death

Interim data from FIDES-02 study of derazantinib in advanced urothelial cancer

Fujitsu and PeptiDream announce milestone under joint research effort

Additional interim data presented for WP-1066 in adult glioblastoma

Direct AMPK activator opposes mitochondrial dysfunction, oxidative stress and inflammation in DPN

New STING agonists identified at Lupin

Sumitomo Dainippon Pharma Oncology presents new PKM2 activators

Shanghai Ringene Biopharma synthesizes new BRD and/or c-Myc inhibitors

AnaptysBio reports topline data from phase II GALLOP study of imsidolimab in GPP

First patient dosed in phase I study of NBTXR-3 in pancreatic cancer

Gossamer Bio presents topline phase II data for GB-001

Targeting Ire1-alpha may reduce cystic fibrosis airway inflammation

CARB-X award supports development of Polyphor antibiotic program

New phase I trial evaluates liposomal hydroxychloroquine TLC-19 for COVID-19

Derazantinib active in intrahepatic cholangiocarcinoma with FGFR2 mutations/amplifications

Allob shows 90% fusion rate at 24 months in phase IIa study in lumbar spinal fusion

FDA grants expanded access to ExoFlo for COVID-19-associated ARDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...